🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Enanta Pharmaceuticals CEO sells $41,444 in stock

Published 12/11/2024, 06:00 AM
ENTA
-

Luly Jay R., President and CEO of Enanta Pharmaceuticals Inc . (NASDAQ:ENTA), a biotech company currently valued at $183 million with a current ratio of 5.21, recently sold a portion of the company's common stock. According to InvestingPro data, the company operates with moderate debt levels while maintaining strong liquidity. According to the SEC filing, Jay R. sold 5,142 shares on December 6, 2024, at a weighted average price of $8.06 per share, totaling approximately $41,444. This transaction was conducted to cover withholding taxes resulting from the settlement of a restricted stock unit award granted in November 2022. Following this sale, Jay R. retains ownership of 801,638 shares in the company. The shares were sold as part of a "sell to cover" transaction, which does not represent a discretionary decision by the executive. The stock is currently trading at $8.64, near its 52-week low of $7.58, with InvestingPro analysis showing additional valuable insights about insider trading patterns and company valuation available to subscribers.

In other recent news, Enanta Pharmaceuticals has seen several key developments. Leerink Partners raised Enanta's price target to $12, maintaining a Market Perform rating, following the company's fiscal fourth-quarter and full-year 2024 financial report which showed royalty revenues of approximately $14.6 million from Mavyret. Despite lower-than-expected revenues, attention is expected to shift to the upcoming release of Phase 2 RSVPEDs trial data for zelicapavir and the progress of Enanta's EDP-323 respiratory syncytial virus (RSV) antiviral.

Baird reduced Enanta's stock price target to $20, maintaining an Outperform rating, following a recent earnings report and in anticipation of upcoming clinical trial results. The trial results could be a critical factor in determining the future potential of Enanta's RSV drug candidate, zelicapavir. H.C. Wainwright reiterated its Buy rating on Enanta shares, emphasizing the company's proficiency in developing impactful antiviral therapies.

Furthermore, Enanta reported promising results from its Phase 2a study of EDP-323, a treatment candidate for RSV. The study demonstrated significant reductions in viral load and clinical symptoms, suggesting a favorable safety profile for the drug. JMP Securities and Baird maintained their Outperform and Market Outperform ratings respectively for Enanta, following Pfizer (NYSE:PFE)'s decision to halt the development of its fusion inhibitor sisunatovir. These are the recent developments in Enanta Pharmaceuticals' ongoing efforts to address unmet medical needs in the treatment of respiratory infections.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.